<DOC>
	<DOCNO>NCT02842021</DOCNO>
	<brief_summary>To assess efficacy safety combination product S2G6T-1 compare monad vehicle , apply twice daily 7 day , treatment symptomatic inflammatory interdigital tinea pedis subject 12 year age old . The result study utilized perform power calculation Phase 3 pivotal trial .</brief_summary>
	<brief_title>Efficacy Safety Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<criteria>1 . Ability willingness sign write informed consent /or assent ( age appropriate ) . 2 . Male Female subject 12 year age old . 3 . A clinical diagnosis interdigital tinea pedis one foot characterize clinical evidence tinea infection . 4 . A sum least five ( 5 ) sign ( erythema scale ) investigator select target foot , score least five ( 5 ) symptom : pruritus ( itch ) burning : sum least twelve ( 12 ) symptom ( pruritus burn ) subject PATSS . 5 . Mycological evidence presence fungi confirm detection fungal hypha microscopic KOH wet mount . 6 . Females childbearing potential must negative urine pregnancy test must agree use effective form contraception study . 7 . Must good general health determine medical history free disease investigator 's opinion might interfere study evaluation . 8 . Must able communicate , able understand study procedure , willing comply study requirement . 1 . The presence confluent diffuse moccasintype tinea pedis . 2 . Negative KOH microscopy test ass presence hypha . 3 . Onychomycosis toenail , involve â‰¥ 20 % area either great toenail involvement five toenail total . 4 . Concurrent tinea infection bacterial skin infection foot . 5 . Female subject pregnant and/or nursing planning pregnancy course trial . 6 . Recent history currently know abuse drug alcohol . 7 . History intolerance hypersensitivity Econazole Nitrate , Mometasone Furoate , imidazole agent . 8 . Presence infection foot disease process might confound treatment evaluation . 9 . Having lifethreatening condition immunocompromised ( e.g. , autoimmune deficiency syndrome , cancer , unstable angina , myocardial infarction ) within last 6 month . 10 . Unable communicate cooperate investigator due language barrier , poor mental development , impaired cerebral function . 11 . Current participation clinical drug research study recent participation clinical trial within 30 day Baseline . 12 . Using follow medication prior Baseline : 1 . Antipruritics , include antihistamine within 3 day ( 72 hour ) . 2 . Topical corticosteroid , antibiotic antifungal therapy within 4 week . 3 . Systemic corticosteroid , antibiotic antifungal therapy within 12 week . 4 . Oral terbinafine itraconazole within 12 week . 5 . Immunosuppressive medication radiation therapy within 12 week . 6 . Any topical medicated topical treatment treatment area ( ) within 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>